GPR120 agonism as a countermeasure against metabolic diseases
详细信息 查看全文
- 作者：Lauren M. Cornall1 ; Michael L. Mathai1 ; Deanne H. Hryciw2 ; Andrew J. McAinch1 ; andrew.mcainch@vu.edu.au" class="auth_mail
- 刊名：Drug Discovery Today
- 出版年：May 2014
- 年：2014
- 卷：19
- 期：5
- 页码：670-679
- 全文大小：2092 K
文摘
- •
GPR120 agonists are new therapeutic targets for treating obesity, diabetes and CVD.
- •
GPR120 is activated by long-chain fatty acids, particularly omega 3 fatty acids.
- •
The expression of GPR120 is altered by obesity.
- •
GPR120 regulates GLP-1 and CCK secretion, insulin signaling and inflammation.
- •
GPR120 agonism mediates adipogenesis and can protect against diet-induced obesity.